QUALITY OF LIFE

Quality of Life of Patients with Lymphomas at Different Time-Points after High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation

QUALITY OF LIFE , , ,

N.E. Mochkin1, D.A. Fedorenko1, V.Ya. Mel’nichenko1, T.I. Ionova2, T.P. Nikitina1,2, K.A. Kurbatova2, A.A. Novik1

1 N.I. Pirogov National Medical and Surgical Center under the Ministry of Health of the Russian Federation, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203

2 International Quality of Life Research Center, 1 office 152, Artilleriiskaya str., Saint Petersburg, Russian Federation, 191014

For correspondence: N.E. Mochkin, PhD, assistant, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203; Tel: +7(495)603-72-17; e-mail: nickmed@yandex.ru

For citation: Mochkin N.E., Fedorenko D.A., Mel’nichenko V.Ya., Ionova T.I., Nikitina T.P., Kurbatova K.A., Novik A.A. Quality of Life of Patients with Lymphomas at Different Time-Points after HighDose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Klin. Onkogematol. 2014; 7(4): 577–582 (In Russ.).

 

ABSTRACT

The article presents results of monitoring of quality of life of 103 patients with lymphomas (non-Hodgkin’s lymphomas, n = 36; Hodgkin’s lymphomas, n = 67) at different stages after high-dose chemotherapy with autologic hematopoietic stem cell transplantation (HDC + HSCT). The majority of patients experienced improvement or stabilization of their quality of life 1 year after the HDC + aHSCT. At that, the response associated with the quality of life and clinical response to the treatment did not coincide in all cases. Obtained results confirm the importance of a comprehensive approach to assessment of the efficacy of the treatment and may be use as a principle marker of patient’s recovery at different time points after the transplantation.

Keywords: quality of life, lymphomas, high-dose chemotherapy, autologic hematopoietic stem cell transplantation.

Accepted: September 16, 2014

Read in PDF (RUS)pdficon

REFERENCES

  1. Colpo A., Hochberg E., Chen Y.B. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma. Oncologist. 2012; 17: 80–90.
  2. d’Amore F., Relander T., Lauritzen G.F. et al. High-dose chemotherapy and autologous stem cell transplantation in previously untreated peripheral T-cell lymphoma — final analysis of a large prospective multicenter study (NLGT-01). Blood (ASH Annual Meeting Abstracts). 2011; 118: 331.
  3. Damon L.E., Johnson J.L., Neidzwiecki D. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J. Clin. Oncol. 2009; 27: 6101–8.
  4. Freidberg J.W. Relapsed/refractory diffuse large B-cell lymphoma. Hematol. Am. Soc. Hematol. Educ. Program. 2011: 498–501.
  5. Geisler C.H., Polstad A., Laurell A. et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008; 112: 2687–93.
  6. Hjermstad M.J., Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation — a review of the literature. Eur. J. Cancer. 1995; 31A(2): 163–73.
  7. Kiss T.L., Abdolell M., Jamal N. et al. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogenic bone marrow transplantation. J. Clin. Oncol. 2002; 20(9); 2334–43.
  8. Anderson K.O., Giralt S.A., Mendoza T.R. et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant. 2007; 39(12): 759–66.
  9. Grant M., Ferrel B., Schmidt G.M. et al. Measurement of quality of life in bone marrow transplantation survivors. Qual. Life Res. 1992; 1(6): 375–84.
  10. Новик А.А., Ионова Т.И., Афанасьев Б.В. и др. Результаты аутоло- гичной трансплантации костного мозга/стволовых кроветворных клеток у больных гемобластозами: клиническая эффективность и показатели ка- чества жизни. Вестник Межнационального центра исследования качества жизни. 2011; 17–18: 22–32. [Novik A.A., Ionova T.I., Afanas’ev B.V. et al. Results of autologic bone marrow transplantation/hematopoietic stem cells transplantation in patients with hemoblastoses: clinical efficacy and parameters of quality of life. Vestnik Mezhnatsional’nogo tsentra issledovaniya kachestva zhizni. 2011; 17–18: 22–32. (In Russ.)]
  11. Rock E.P., Kennedy D.L., Furness M.H. et al. Patient-reported outcomes supporting anticancer product approvals. J. Clin. Oncol. 2007; 25: 5094–9.
  12. Fairclough D. Patient-reported outcomes as endpoints in medical research. Sta. Meth. Med. Res. 2004; 13: 115–38.
  13. Gondek K., Sagnier P., Gichrist K., Wooley J. Current status of patientreported outcomes in industry-sponsored oncology clinical trials and product labels. J. Clin. Oncol. 2007; 25(32): 5087–93.
  14. Steven B. Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. J. Clin. Oncol. 2007; 25(32): 5049–50.
  15. Watkins B. Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the national cancer institute-sponsored clinical trials networks. J. Clin. Oncol. 2007; 25(32): 5051–7.
  16. Molassiotis A., Van der Akker O., Milligan D. et al. Quality of life in longterm survivors of marrow transplantation: Comparison with a matched group receiving maintenance chemotherapy. Bone Marrow Transplant. 1996; 17: 249–58.
  17. Руководство по исследованию качества жизни в медицине, 3-е изд., перераб. и доп. Под ред. Ю.Л. Шевченко. М.: Изд-во РАЕН, 2012. [Shevchenko Yu.L., ed. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine (Guidelines for evaluation of the quality of life in medicine). 3rd revised edition. Moscow: RAEN Publ.; 2012.]
  18. Neitzert C.S., Ritvo P., Dancey J. et al. The psychosocial impact of bone marrow transplantation: A review of the literature. Bone Marrow Transplant. 1998; 22: 409–22.
  19. Wingard J.R. Quality of life following bone marrow transplantation. Curr. Opin. Oncol. 1998; 10: 108–11.
  20. Chao N.J., Tierney D.K., Bloom J.R. et al. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood. 1992; 80: 825–30.
  21. Cohen M.Z., Mendoza T., Neumann J. et al. Longitudinal assessment of symptoms and quality of life: Differences by ablative and nonablative blood and marrow transplantation. J. Clin. Oncol. 2004; 22(15S): 6630.
  22. Ganz P., Gotay C. Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials; Lessons Learned and Future Directions. J. Clin. Oncol. 2007; 25(32): 5063–9.
  23. Novik A., Salek S., Ionova T. Patient-reported outcomes in hematology. Guidelines. EHA SWG Quality of Life and Symptoms. Litoprint. Genoa, 2012.
  24. Hays R.D., Sherbourne C.D., Mazel R.M. User’s Manual for Medical Outcomes Study (MOS) Core measures of health-related quality of life. RAND Corporation, MR-162-RC. Available at www.rand.org.
  25. Новик А.А., Ионова Т.И. Исследование качества жизни в медицине: Учебное пособие для вузов. Под ред. Ю.Л. Шевченко. М.: ГЭОТАР-Медиа, 2004. [Novik A.A., Ionova T.I. Issledovanie kachestva zhizni v meditsine (Evaluation of the quality of life in medicine). Textbook for institutes of higher education. Shevchenko Yu.L., ed. Moscow: GEOTAR-Media Publ.; 2004.]
  26. Новик А.А., Ионова Т.И. Интегральный показатель качества жизни — новая категория в концепции исследования качества жизни. Вестник Межнационального центра исследования качества жизни. 2006; 7–8: 7–8. [Novik A.A., Ionova T.I. Integral assessment of quality of life is a new category in the concept of evaluation of quality of life. Vestnik Mezhnatsional’nogo tsentra issledovaniya kachestva zhizni. 2006; 7–8: 7–8. (In Russ.)]

Value of Patient-Reported Outcomes in Oncohematology

QUALITY OF LIFE , , ,

T.I. Ionova1, S. Salek2, Е. Оliva3

1 International Quality of Life Research Center, 1 office 152, Artilleriiskaya str., Saint Petersburg, Russian Federation, 191014

2 Cardiff University, Pharmacoeconomics Department, Redwood Building King Edward VII Avenue Cardiff, CF10 3NB, UK

3 Hematology Division, Azienda Ospedaliera B-M-M, Via Melacrino, 89100 Regio Calabria, Italy

For correspondence: T.I. Ionova, DSci, Professor, 1 office 152, Artilleriiskaya str., Saint Petersburg, Russian Federation, 191014; Tel: +7(812)579-61-38; e-mail: tation16@gmail.com

For citation: Ionova T.I., Salek S., Oliva E. Value of Patient-Reported Outcomes in Oncohematology. Klin. Onkogematol. 2014; 7(4): 573–576 (In Russ.).

ABSTRACT

One of priorities of modern medical science is the patient-oriented care. This approach presupposes that patient management should be based not only on analysis of clinical and lab test findings but also on reports made by the patient himself. These reports permit to perform a thorough analysis of patient’s problems and to obtain more data on the treatment effectiveness. Quality of life (QoL) and symptoms are key factors in patient-reported outcomes (PRO). The past decade has been characterized by increased attention paid by the medical community to patient’s own sensations throughout the treatment. The importance of this principle is confirmed by the fact that “Quality of Life in Hematology” was declared as the 2012–2013 theme of the year by the European Hematology Association. Partient-reported outcomes permit to obtain information that cannot be obtained from other sources. It is especially important when new treatment methods are selected and when new approaches to palliative care are developed.

Keywords: patient-reported outcomes, quality of life, symptoms, clinical practice.

Accepted: September 15, 2014

Read in PDF (RUS)pdficon

REFERENCES

  1. Doward L.C., McKenna S.P. Defining patient-reported outcomes. Value Health. 2004; 7(Suppl. 1): S4–S8.
  2. Efficace F., Novik A., Vignetti M. et al. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here? Haematologica 2007; 92(12): 1596–8.
  3. Gorodokin G.I., Novik A.A. Quality of cancer care. Ann. Oncol. 2005; 16: 991. 4. Guidelines. Patient-reported outcomes in hematology. The EHA SWG «Quality of life and Symptoms». Forum Service Editore. Genoa, 2012.
  4. Osoba D. Translating the science of patient-reported outcomes assessment into clinical practice. J. N. C. I. Monogr. 2007; 37: 5–11.
  5. US Food and Drug Administration: Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from website U.S. FDA, Clinical/Medical, 2009. http:/www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM193282.pdf.
  6. Руководство по исследованию качества жизни в медицине, 3-е изд., перераб. и доп. Под ред. Ю.Л. Шевченко. М.: Изд-во РАЕН, 2012. [Shevchenko Yu.L., ed. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine (Guidelines for evaluation of the quality of life in medicine). 3rd revised edition. Moscow: RAEN Publ.; 2012.]
  7. World Health Organization: Constitution of the World Health Organization, in Handbook of Basic Documents. Geneva, 1948.
  8. Salek S., Ionova T., Oliva E., EHA SWG «Quality of Life and Symptoms». Patients’ needs in hematology: whose perspectives? Haematologica. 2013; 98(6): 828–30.
  9. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине. СПб.: Нева, ОЛМА-ПРЕСС Звездный мир. 2002. [Novik A.A., Ionova T.I. Rukovodstvo po issledovaniyu kachestva zhizni v meditsine. (Guidelines for evaluation of the quality of life in medicine.) Saint Petersburg: Neva, OLMA-PRESS Zvezdnyi mir Publ.; 2002.]
  10. Fayers P., Machin D. Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. Weinheim: John Wiley & Sons, 2007.
  11. Fitzpatrick R., Davey C., Buxton M.J., Jones D.R. Evaluating patient-based outcome measures for use in clinical trials. Hlth. Technol. Ass. 1998; 2(14): 1–74.
  12. Strasser-Weippl K., Ludwig H. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. Eur. J. Haematol. 2008; 81(5): 374–9.
  13. Oliva E., Nobile F., Alimena F. et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011; 96(5): 696–702.
  14. WHO Definition of Palliative Care. World Health Organization. Retrieved May, 2014